Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization

A randomized clinical trial

C. M. Den Hoed, A. C. De Vries, P. B F Mensink, C. M. Dierikx, Hidekazu Suzuki, L. Capelle, H. Van Dekken, R. Ouwendijk, E. J. Kuipers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Antibiotic-based regimens are frequently used for the treatment of Helicobacter pylori infection. These regimens fail to eradicate H pylori in 15% to 40% of patients, primarily due to antimicrobial resistance and insufficient patient compliance. Effective prevention and eradication of H pylori by passive immunization with orally administered bovine antibodies has been demonstrated in animal studies, and may serve as an alternative therapy in humans. OBJECTIVE: To study the efficacy and safety of orally administered bovine anti-H pylori antibodies for the reduction of intragastric bacterial load and eradication of H pylori in humans. METHODS: Dairy cows were immunized against H pylori. After confirmation of the presence of anti-H pylori antibodies in the milk, the milk was subsequently processed into a whey protein concentrate (WPC). In a prospective, double-blind, placebo-controlled randomized clinical trial, H pylori-infected subjects were randomly assigned to treatment with the WPC preparation or placebo. Study medication was continued for 28 days; subjects were followed-up for 56 days. RESULTS: Of the 30 subjects included, 27 completed the protocol. Of these 27 evaluable subjects, 14 were treated with WPC and 13 with placebo. There was no significant difference in urea breath test decrease between the WPC- and placebo-treated group (P=0.75). H pylori-associated gastritis and density were not significantly reduced in either group after treatment (P>0.05 for all). CONCLUSION: Bovine antibody-based oral immunotherapy appears to be safe, but does not significantly reduce intragastric H pylori density in humans. Further studies are needed to determine whether WPC treatment has additional value to conventional antibiotic treatment for H pylori.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalCanadian Journal of Gastroenterology
Volume25
Issue number4
Publication statusPublished - 2011 Apr

Fingerprint

Pylorus
Helicobacter pylori
Immunotherapy
Randomized Controlled Trials
Antibodies
Placebos
Milk
Anti-Bacterial Agents
Therapeutics
Breath Tests
Passive Immunization
Bacterial Load
Helicobacter Infections
Gastritis
Patient Compliance
Complementary Therapies
Urea
Whey Proteins
Safety

Keywords

  • Eradication treatment
  • Gastritis
  • H pylori
  • Immunotherapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Den Hoed, C. M., De Vries, A. C., Mensink, P. B. F., Dierikx, C. M., Suzuki, H., Capelle, L., ... Kuipers, E. J. (2011). Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial. Canadian Journal of Gastroenterology, 25(4), 207-213.

Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization : A randomized clinical trial. / Den Hoed, C. M.; De Vries, A. C.; Mensink, P. B F; Dierikx, C. M.; Suzuki, Hidekazu; Capelle, L.; Van Dekken, H.; Ouwendijk, R.; Kuipers, E. J.

In: Canadian Journal of Gastroenterology, Vol. 25, No. 4, 04.2011, p. 207-213.

Research output: Contribution to journalArticle

Den Hoed, CM, De Vries, AC, Mensink, PBF, Dierikx, CM, Suzuki, H, Capelle, L, Van Dekken, H, Ouwendijk, R & Kuipers, EJ 2011, 'Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial', Canadian Journal of Gastroenterology, vol. 25, no. 4, pp. 207-213.
Den Hoed, C. M. ; De Vries, A. C. ; Mensink, P. B F ; Dierikx, C. M. ; Suzuki, Hidekazu ; Capelle, L. ; Van Dekken, H. ; Ouwendijk, R. ; Kuipers, E. J. / Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization : A randomized clinical trial. In: Canadian Journal of Gastroenterology. 2011 ; Vol. 25, No. 4. pp. 207-213.
@article{399d40fed2604eb39204b42c59b43fe1,
title = "Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial",
abstract = "BACKGROUND: Antibiotic-based regimens are frequently used for the treatment of Helicobacter pylori infection. These regimens fail to eradicate H pylori in 15{\%} to 40{\%} of patients, primarily due to antimicrobial resistance and insufficient patient compliance. Effective prevention and eradication of H pylori by passive immunization with orally administered bovine antibodies has been demonstrated in animal studies, and may serve as an alternative therapy in humans. OBJECTIVE: To study the efficacy and safety of orally administered bovine anti-H pylori antibodies for the reduction of intragastric bacterial load and eradication of H pylori in humans. METHODS: Dairy cows were immunized against H pylori. After confirmation of the presence of anti-H pylori antibodies in the milk, the milk was subsequently processed into a whey protein concentrate (WPC). In a prospective, double-blind, placebo-controlled randomized clinical trial, H pylori-infected subjects were randomly assigned to treatment with the WPC preparation or placebo. Study medication was continued for 28 days; subjects were followed-up for 56 days. RESULTS: Of the 30 subjects included, 27 completed the protocol. Of these 27 evaluable subjects, 14 were treated with WPC and 13 with placebo. There was no significant difference in urea breath test decrease between the WPC- and placebo-treated group (P=0.75). H pylori-associated gastritis and density were not significantly reduced in either group after treatment (P>0.05 for all). CONCLUSION: Bovine antibody-based oral immunotherapy appears to be safe, but does not significantly reduce intragastric H pylori density in humans. Further studies are needed to determine whether WPC treatment has additional value to conventional antibiotic treatment for H pylori.",
keywords = "Eradication treatment, Gastritis, H pylori, Immunotherapy",
author = "{Den Hoed}, {C. M.} and {De Vries}, {A. C.} and Mensink, {P. B F} and Dierikx, {C. M.} and Hidekazu Suzuki and L. Capelle and {Van Dekken}, H. and R. Ouwendijk and Kuipers, {E. J.}",
year = "2011",
month = "4",
language = "English",
volume = "25",
pages = "207--213",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "4",

}

TY - JOUR

T1 - Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization

T2 - A randomized clinical trial

AU - Den Hoed, C. M.

AU - De Vries, A. C.

AU - Mensink, P. B F

AU - Dierikx, C. M.

AU - Suzuki, Hidekazu

AU - Capelle, L.

AU - Van Dekken, H.

AU - Ouwendijk, R.

AU - Kuipers, E. J.

PY - 2011/4

Y1 - 2011/4

N2 - BACKGROUND: Antibiotic-based regimens are frequently used for the treatment of Helicobacter pylori infection. These regimens fail to eradicate H pylori in 15% to 40% of patients, primarily due to antimicrobial resistance and insufficient patient compliance. Effective prevention and eradication of H pylori by passive immunization with orally administered bovine antibodies has been demonstrated in animal studies, and may serve as an alternative therapy in humans. OBJECTIVE: To study the efficacy and safety of orally administered bovine anti-H pylori antibodies for the reduction of intragastric bacterial load and eradication of H pylori in humans. METHODS: Dairy cows were immunized against H pylori. After confirmation of the presence of anti-H pylori antibodies in the milk, the milk was subsequently processed into a whey protein concentrate (WPC). In a prospective, double-blind, placebo-controlled randomized clinical trial, H pylori-infected subjects were randomly assigned to treatment with the WPC preparation or placebo. Study medication was continued for 28 days; subjects were followed-up for 56 days. RESULTS: Of the 30 subjects included, 27 completed the protocol. Of these 27 evaluable subjects, 14 were treated with WPC and 13 with placebo. There was no significant difference in urea breath test decrease between the WPC- and placebo-treated group (P=0.75). H pylori-associated gastritis and density were not significantly reduced in either group after treatment (P>0.05 for all). CONCLUSION: Bovine antibody-based oral immunotherapy appears to be safe, but does not significantly reduce intragastric H pylori density in humans. Further studies are needed to determine whether WPC treatment has additional value to conventional antibiotic treatment for H pylori.

AB - BACKGROUND: Antibiotic-based regimens are frequently used for the treatment of Helicobacter pylori infection. These regimens fail to eradicate H pylori in 15% to 40% of patients, primarily due to antimicrobial resistance and insufficient patient compliance. Effective prevention and eradication of H pylori by passive immunization with orally administered bovine antibodies has been demonstrated in animal studies, and may serve as an alternative therapy in humans. OBJECTIVE: To study the efficacy and safety of orally administered bovine anti-H pylori antibodies for the reduction of intragastric bacterial load and eradication of H pylori in humans. METHODS: Dairy cows were immunized against H pylori. After confirmation of the presence of anti-H pylori antibodies in the milk, the milk was subsequently processed into a whey protein concentrate (WPC). In a prospective, double-blind, placebo-controlled randomized clinical trial, H pylori-infected subjects were randomly assigned to treatment with the WPC preparation or placebo. Study medication was continued for 28 days; subjects were followed-up for 56 days. RESULTS: Of the 30 subjects included, 27 completed the protocol. Of these 27 evaluable subjects, 14 were treated with WPC and 13 with placebo. There was no significant difference in urea breath test decrease between the WPC- and placebo-treated group (P=0.75). H pylori-associated gastritis and density were not significantly reduced in either group after treatment (P>0.05 for all). CONCLUSION: Bovine antibody-based oral immunotherapy appears to be safe, but does not significantly reduce intragastric H pylori density in humans. Further studies are needed to determine whether WPC treatment has additional value to conventional antibiotic treatment for H pylori.

KW - Eradication treatment

KW - Gastritis

KW - H pylori

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=80054736163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054736163&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 207

EP - 213

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 4

ER -